NEJM: Patient resensitized to Xalkori

A study published in the New England Journal of Medicine said a patient with metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) regained sensitivity to Xalkori crizotinib after receiving lorlatinib ( PF-06463922). The authors said that two mutations acquired during sequential treatment with the ALK inhibitors changed ALK protein structure to favor binding of Xalkori.

Pfizer Inc. (NYSE:PFE) developed both treatments. ...